By The ASCO Post Staff Posted: 12/7/2022 11:47:00 AM Last Updated: 12/7/2022 1:32:29 PM Second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to significantly longer overall survival compared with ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer,…
The phase III CONTACT-01 trial evaluated atezolizumab plus cabozantinib vs docetaxel in patients with metastatic NSCLC after they had received checkpoint inhibitor treatment and chemotherapy.
A recent study examined whether glucagon-like peptide (GLP)-1 receptor agonists are associated with an increased risk of thyroid cancer.
In a single-center phase II trial, cabozantinib monotherapy showed activity in adult patients with advanced adrenocortical carcinoma.
Investigators have uncovered new genetic variants that may predispose certain female patients to prevalent or persistent HPV infections and increase their risk of developing cervical…
In a single-center phase II trial, cabozantinib monotherapy showed activity in adult patients with advanced adrenocortical carcinoma.
The phase III ALINA trial has shown significantly improved disease-free survival with adjuvant alectinib vs platinum-based chemotherapy in patients with resected ALK-positive NSCLC.
The combination of immunotherapy, targeted therapy, and chemotherapy could be the new standard first-line treatment of patients with high-grade, advanced ovarian cancer with BRCA wild-type,…
The phase III SENOMAC trial showed noninferiority in recurrence-free survival with sentinel node biopsy alone vs completion axillary node dissection in patients with breast cancer…
The phase III KEYNOTE-412 trial showed no significant improvement in event-free survival with the addition of pembrolizumab to concurrent chemoradiotherapy in newly diagnosed patients with…
Researchers may have uncovered the mechanisms behind the development of targeted therapy resistance in melanoma.
